Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA) - Hong Kong, China, 24 - 27 June 2002
(2002; 166 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAbbreviations and acronyms used in this report
Abrir esta carpeta y ver su contenidoOpening ceremony
Cerrar esta carpetaHerbal medicines
Ver el documentoCurrent status of traditional Chinese medicines in China
Ver el documentoRegulation of traditional Chinese medicines in Hong Kong, China
Ver el documentoProposed regulations for natural health products in Canada
Ver el documentoHow regulation of herbal medicines was established in Thailand
Ver el documentoHerbal medicine in the Islamic Republic of Iran
Ver el documentoTraditional herbal medicines: an update on European Union activities
Ver el documentoRegulation of herbal medicines in Ghana
Ver el documentoRecommendations
Abrir esta carpeta y ver su contenidoKeynote address
Abrir esta carpeta y ver su contenidoSafety of blood-derived products
Abrir esta carpeta y ver su contenidoAntimicrobial resistance - new initiatives
Abrir esta carpeta y ver su contenidoHarmonization I
Abrir esta carpeta y ver su contenidoHarmonization II
Abrir esta carpeta y ver su contenidoProtection of trial subjects in clinical trials
Abrir esta carpeta y ver su contenidoRegulating biotechnology products
Abrir esta carpeta y ver su contenidoRegulatory challenges: health sector reform and drug regulatory capacity
Abrir esta carpeta y ver su contenidoAccess to drugs and vaccines I
Abrir esta carpeta y ver su contenidoAccess to drugs and vaccines II
Abrir esta carpeta y ver su contenidoCounterfeit pharmaceutical products
Abrir esta carpeta y ver su contenidoHomoeopathy
Abrir esta carpeta y ver su contenidoSafety monitoring
Abrir esta carpeta y ver su contenidoE-Commerce
Abrir esta carpeta y ver su contenidoCurrent topics
Abrir esta carpeta y ver su contenidoRegulatory challenges of new technologies
Ver el documentoList of participants
Ver el documentoBack cover
 

Recommendations

1. Member States, together with WHO, should define criteria and standards for herbal medicines, health or functional foods, and dietary supplements. WHO should continue to develop guidelines on the assessment of safety, efficacy and quality control of herbal medicinal products and herbal combinations.

2. The safe use of herbal medicines is a major concern for governments and consumers. WHO should provide guidance to countries wishing to establish safety monitoring systems or to expand existing systems to monitor and report adverse reactions to herbal medicines. Member States should strengthen their postmarketing surveillance systems for herbal medicines. Such systems should involve health care providers, consumers and manufacturers.

3. WHO should support countries in developing sources of information on herbal medicines while facilitating informationsharing among countries. WHO should provide guidance to governments and nongovernmental organizations (NGOs) on how to develop information and educational programmes on the proper use of herbal medicines for the public.

4. WHO should provide guidance for governments and NGOs on training of traditional medicine providers, and promote communication with other health workers.

5. Member States should seek funds to support research on herbal medicines.

6. Progress should be reported back to the ICDRA.

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013